Novo Nordisk and Aspect Biosystems have announced the expansion of their strategic partnership, entering a new phase focused on developing advanced cellular medicines for diabetes that could potentially deliver disease-modifying or curative outcomes. The move builds on a collaboration launched in 2023 and reflects both companies’ shared ambition to accelerate innovative therapies for people living with serious metabolic diseases.
Under the expanded agreement, Aspect Biosystems has acquired rights to stem cell–derived islet cell technologies and hypoimmune cell engineering technologies from Novo Nordisk. Aspect will now take the lead on development, manufacturing, and commercialisation of resulting cellular medicines. Novo Nordisk, meanwhile, will retain defined rights to increase its involvement during later-stage development and commercialisation, allowing flexibility as programs advance toward the clinic and market.
As part of the transaction, Novo Nordisk will make an additional equity investment in Aspect and provide research funding to support continued development of the therapies. Novo Nordisk will also be eligible to receive milestone payments and royalties tied to future product sales, aligning long-term incentives between the two companies.
The agreement also includes the integration of select Novo Nordisk cell therapy research, development, and manufacturing capabilities from the United States and Denmark into Aspect’s Canada-based platform. This transfer of expertise is expected to strengthen Aspect’s end-to-end capabilities, from early research through scalable manufacturing, while expanding access to specialized talent in cellular medicine.
Executives from both companies highlighted the strategic fit of the partnership. Novo Nordisk emphasized its century-long commitment to improving the lives of people with diabetes and its continued focus on innovation in type 1 diabetes through both internal research and external collaborations. Aspect, in turn, pointed to the combination of Novo Nordisk’s global diabetes leadership with its own cell therapy expertise and agile biotechnology model.
Aspect’s proprietary platform is being applied to develop a new class of allogeneic, off-the-shelf cellular medicines aimed at serious metabolic and endocrine diseases. Among the most notable programs is an islet replacement therapy for type 1 diabetes designed to restore blood glucose control without the need for chronic immune suppression. By enabling scalable manufacturing and broader patient access, the partners aim to move closer to functional cures that could transform diabetes care worldwide.